Immutep (IMMP) has released an update.
Immutep Limited has announced the successful completion of both its institutional placement and the institutional component of its pro rata entitlement offer, with strong support from institutional investors and a 100% take-up rate. The company raised approximately A$89.6 million through the offer, contributing to a total expected raise of A$100.2 million including the upcoming retail component. Immutep is advancing its clinical program in cancer treatment and has received strong backing from shareholders, expressing confidence in its future prospects.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
